Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04508647
Title Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Colorado, Denver
Indications

marginal zone B-cell lymphoma

follicular lymphoma

Therapies

Ublituximab

Ublituximab + Umbralisib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.